{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:45:45Z","timestamp":1790282745395,"version":"4.1.0"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.2967\/jnumed.121.262045","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T19:10:37Z","timestamp":1627585837000},"page":"536-542","source":"Crossref","is-referenced-by-count":130,"title":["First-in-Humans Evaluation of a PD-L1\u2013Binding Peptide PET Radiotracer in Non\u2013Small Cell Lung Cancer Patients"],"prefix":"10.2967","volume":"63","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"2022042908200986000_63.4.536.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2022042908200986000_63.4.536.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"2022042908200986000_63.4.536.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2022042908200986000_63.4.536.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2022042908200986000_63.4.536.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30407-3"},{"key":"2022042908200986000_63.4.536.6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol."},{"key":"2022042908200986000_63.4.536.7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-med-050217-025205","article-title":"PD-1 blockade in early-stage lung cancer","volume":"70","author":"Rosner","year":"2019","journal-title":"Annu Rev Med."},{"key":"2022042908200986000_63.4.536.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2022042908200986000_63.4.536.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3146"},{"key":"2022042908200986000_63.4.536.10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol."},{"key":"2022042908200986000_63.4.536.11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2290"},{"key":"2022042908200986000_63.4.536.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70009-7"},{"key":"2022042908200986000_63.4.536.13","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun."},{"key":"2022042908200986000_63.4.536.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224170"},{"key":"2022042908200986000_63.4.536.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199596"},{"key":"2022042908200986000_63.4.536.16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med."},{"key":"2022042908200986000_63.4.536.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3477"},{"key":"2022042908200986000_63.4.536.18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2967\/jnumed.119.240895","article-title":"Quantification of PD-L1 expression with 18F-BMS-986192 PET\/CT in patients with advanced-stage non-small cell lung cancer","volume":"61","author":"Huisman","year":"2020","journal-title":"J Nucl Med."},{"key":"2022042908200986000_63.4.536.19","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1021\/acs.molpharmaceut.8b00399","article-title":"Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer","volume":"15","author":"De Silva","year":"2018","journal-title":"Mol Pharm."},{"key":"2022042908200986000_63.4.536.20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J Clin Invest."},{"key":"2022042908200986000_63.4.536.21","unstructured":"U.S. Food and Drug Administration. Dako PD-L1 IHC 22C3 pharmDx. September 2015. FDA website. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150013c.pdf. Accessed January 19, 2022."},{"key":"2022042908200986000_63.4.536.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2022042908200986000_63.4.536.23","doi-asserted-by":"crossref","first-page":"10215","DOI":"10.18632\/oncotarget.7143","article-title":"A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors","volume":"7","author":"Chatterjee","year":"2016","journal-title":"Oncotarget."},{"key":"2022042908200986000_63.4.536.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2022042908200986000_63.4.536.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2022042908200986000_63.4.536.26","doi-asserted-by":"crossref","first-page":"1536012119852189","DOI":"10.1177\/1536012119852189","article-title":"Development of [18F]FPy-WL12 as a PD-L1 specific PET imaging peptide","volume":"18","author":"Lesniak","year":"2019","journal-title":"Mol Imaging."},{"key":"2022042908200986000_63.4.536.27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2016.12.156","article-title":"Rapid PD-L1 detection in tumors with PET using a highly specific peptide","volume":"483","author":"Chatterjee","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"2022042908200986000_63.4.536.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.icrp.2012.02.001"},{"key":"2022042908200986000_63.4.536.29","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J Nucl Med."},{"key":"2022042908200986000_63.4.536.30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/14737159.2017.1398083","article-title":"PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?","volume":"17","author":"Hofman","year":"2017","journal-title":"Expert Rev Mol Diagn."},{"key":"2022042908200986000_63.4.536.31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288"},{"key":"2022042908200986000_63.4.536.32","doi-asserted-by":"publisher","DOI":"10.7150\/thno.13502"},{"key":"2022042908200986000_63.4.536.33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/RLU.0000000000002603","article-title":"Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1\/PD-L1 blockade therapy in patients with non-small cell lung cancer","volume":"44","author":"Beer","year":"2019","journal-title":"Clin Nucl Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T11:22:14Z","timestamp":1651231334000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2967\/jnumed.121.262045"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262045","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}